# ClinicalTrials.gov record NCT02944500

> PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct02944500-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02944500-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02944500-liraglutide-v1.json
- Content SHA-256: `35ab46a46fbf499ac1249fd51202350328e69df0363e4dd0d5e4c38bfe99e5c8`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02944500 ([`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`](#source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`](#source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`](#source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`](#source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92))

## Sources

<a id="source-ctg-observation-nct02944500-2026-05-01-2ab184f58b92"></a>
- **ClinicalTrials.gov record NCT02944500 · retained source version 2026-05-01:2ab184f58b92a10a2d09128f3081f01713ff9c38f68bd2ddb16824bed4b684ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02944500) (`ctg-observation-nct02944500-2026-05-01-2ab184f58b92`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02944500." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02944500-liraglutide-v1.json SHA-256: 35ab46a46fbf499ac1249fd51202350328e69df0363e4dd0d5e4c38bfe99e5c8.